|1.||Giamarellos-Bourboulis, Evangelos J: 13 articles (04/2014 - 01/2004)|
|2.||Kohno, Shigeru: 13 articles (01/2012 - 01/2002)|
|3.||Lam, S K: 9 articles (01/2006 - 02/2000)|
|4.||Coleman, Morton: 8 articles (01/2016 - 09/2002)|
|5.||Gisbert, Javier P: 8 articles (02/2015 - 09/2005)|
|6.||Gasbarrini, A: 8 articles (08/2014 - 01/2000)|
|7.||Mukae, Hiroshi: 8 articles (03/2012 - 05/2002)|
|8.||Kim, Nayoung: 7 articles (04/2015 - 09/2003)|
|9.||Niesvizky, Ruben: 7 articles (12/2014 - 09/2002)|
|10.||Ojetti, V: 7 articles (08/2014 - 01/2000)|
08/14/2014 - "The efficacy of triple therapy for Helicobacter pylori infection has dramatically declined over the last decade, largely related to increasing clarithromycin resistance rates. "
10/01/2002 - "The infection resolved completely with surgery and antibiotic therapy with clarithromycin 500 mg twice daily orally for 3 months. "
01/01/2015 - "Here, we report that respiratory infection with PCD and intralobar sequestration (ILS) were treated successfully with clarithromycin before the surgical resection of ILS. "
12/01/2014 - "Clarithromycin for first-line treatment of Helicobacter pylori infection after culture in high-resistance regions."
04/17/2007 - "pylori infection and is statistically significantly more effective in patients with clarithromycin-resistant strains. "
09/01/2003 - "Clarithromycin, a macrolide with immunomodulatory effect, was included in the antibiotic regimen of the progressive pneumonia, followed by rapid amelioration and remission of clinical and laboratory findings. "
02/01/2011 - "Macrolide resistance in Mycoplasma pneumoniae has been reported in Japan, but the results of this surveillance study showed that clarithromycin is effective in treating adult atypical pneumonia."
02/01/1991 - "Efficacy was comparable between treatment groups: 26 of 34 patients (76%) treated with clarithromycin were clinically cured, including four with atypical pneumonia. "
05/01/2004 - "Using an immunocompromised murine pneumonia model, this study evaluated in vivo efficacy of human simulated exposures of clarithromycin for 62 isolates of Streptococcus pneumoniae considered resistant by current methods of breakpoint determinations. "
12/01/1991 - "In this study the safety and efficacy of orally administered clarithromycin (500 to 1,000 mg bid) in the treatment of Legionella pneumonia were evaluated. "
|3.||Duodenal Ulcer (Curling's Ulcer)
01/01/2006 - "When patients with non-susceptibility to clarithromycin were excluded, eradication rates were >80% for both gastric and duodenal ulcers in the two groups. "
01/01/2002 - "[Fromilide (clarithromycin) in eradication of Helicobacter pylori in patients with duodenal ulcer]."
01/01/2002 - "Comparison of two treatment regimens of eradication treatment of duodenal ulcer (DU) associated with Helicobacter pylori based on fromilid (clarithromycin). "
01/01/2002 - "[Fromilid (clarithromycin) in eradication patients in patients with duodenal ulcer associated with Helicobacter pylori (comparison of two treatment variations)]."
06/01/1999 - "pylori in patients with duodenal ulcer, clarithromycin, 500 mg bid for 2 weeks, with RBC, 400 mg bid for 4 weeks, is equivalent to clarithromycin, 500 mg tid with RBC. "
03/01/1992 - "The new macrolide, clarithromycin, appears to be effective and well-tolerated in the treatment of acute exacerbation of chronic bronchitis."
02/01/2005 - "Comparative efficacy of once daily, 5-day short-course therapy with clarithromycin extended-release versus twice daily, 7-day therapy with clarithromycin immediate-release in acute bacterial exacerbation of chronic bronchitis."
03/01/2007 - "Outpatients with acute bacterial exacerbation of chronic bronchitis were treated with clarithromycin 250 mg twice daily or clarithromycin in modified release formulation 500 mg once daily, for 7 days in a prospective, randomized, single-centre study. "
02/01/2005 - "The objective of this study was to compare the efficacy, tolerability, and safety of two clarithromycin regimens, extended-release (ER) 1000 mg once daily for 5 days and immediate-release (IR) 500 mg twice daily for 7 days, in the treatment of acute bacterial exacerbation of chronic bronchitis (ABECB). "
01/01/2003 - "Two randomized trials in patients with acute exacerbations of chronic bronchitis (AECB) showed that a 7-day course of clarithromycin extended-release 1000 mg once daily produced clinical cure rates of 83% and 85% and bacteriologic cure rates of 86% and 92% at the test-of-cure study visit. "
|5.||Acquired Immunodeficiency Syndrome (AIDS)
02/08/1993 - "A multicenter open trial was conducted to assess the antimicrobial activity and clinical efficacy of clarithromycin--a new macrolide antibiotic--against disseminated M avium in 77 patients with late-stage AIDS. "
11/01/2003 - "This multicenter, randomized, open-label phase 3 clinical trial compared the safety and efficacy of 3 clarithromycin-containing combination regimens for the treatment of disseminated Mycobacterium avium complex (MAC) disease in persons with acquired immunodeficiency syndrome. "
09/01/2005 - "We conducted a randomized, crossover trial in which 14 AIDS patients received clarithromycin ER, 1000 mg once daily, and clarithromycin IR, 500 mg bid, each for 1 week, with pharmacokinetic sampling at the end of each week. "
12/01/2004 - "The availability of clarithromycin (CAM) has been established through many randomized clinical trials for disseminated MAC complicated AIDS, but for pulmonary MAC, complete cure is still difficult if we use CAM including regimen. "
07/01/1999 - "A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients: excess mortality associated with high-dose clarithromycin. "
|10.||Anti-Bacterial Agents (Antibiotics)
|1.||Drug Therapy (Chemotherapy)